1. 97P Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin lymphoma in real clinical practice. (December 2022) Authors: Fedorova, L.; Smykova, O.; Chekalov, A.; Lepik, E.; Markelov, V.; Popova, M.; Kondakova, E.; Moiseev, I.; Lepik, K.; Mikhailova, N.; Kulagin, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA. (12th June 2019) Authors: Rogacheva, Y.; Popova, M.; Lepik, K.; Kondakova, E.; Zalyalov, Y.; Stelmah, L.; Volkova, A.; Nikolaev, I.; Goloshchapov, O.; Barhatov, I.; Bondarenko, S.; Moiseev, I.; Baykov, V.; Mikhailova, N.; Klimko, N.; Afanasyev, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA. (23rd June 2022) Authors: Fedorova, L.; Lepik, K.; Mikhailova, N.; Kondakova, E.; Komarova, Y.; Popova, M.; Kotselyabina, P.; Borzenkova, E.; Baykov, V.; Moiseev, I.; Kulagin, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 970 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS. (12th June 2019) Authors: Lepik, K.; Mikhaylova, N.; Kondakova, E.; Tsvetkova, L.; Zalyalov, Y.; Borzenkova, E.; Moiseev, I.; Baykov, V.; Nikitina, T.; Porfir'eva, N.; Ionova, T.; Afanasyev, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA AFTER DISCONTINUATION OF THE THERAPY WITH IMMUNE CHECKPOINT INHIBITORS. (12th June 2019) Authors: Fedorova, L.; Lepik, K.; Mikhailova, N.; Kondakova, E.; Zalyalov, Y.; Baykov, V.; Babenko, E.; Borzenkova, E.; Tsvetkova, L.; Stelmakh, L.; Afanasyev, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRST PAVLOV STATE MEDICAL UNIVERSITY OF SAINT‐PETERSBURG EXPERIENCE. (12th June 2019) Authors: Lepik, E.; Kozlov, A.; Borzenkova, E.; Zalyalov, Y.; Lepik, K.; Kondakova, E.; Baykov, V.; Moiseev, I.; Mikhaylova, N.; Afanasyev, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗